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Abstract 
Background: HIV‑1 capsid influences viral uncoating and nuclear import. Some capsid is detected in the nucleus but 
it is unclear if it has any function. We reported that the antibiotic Coumermycin‑A1 (C‑A1) inhibits HIV‑1 integration 
and that a capsid mutation confers resistance to C‑A1, suggesting that capsid might affect post‑nuclear entry steps.
Results: Here we report that C‑A1 inhibits HIV‑1 integration in a capsid‑dependent way. Using molecular docking, we 
identify an extended binding pocket delimited by two adjacent capsid monomers where C‑A1 is predicted to bind. 
Isothermal titration calorimetry confirmed that C‑A1 binds to hexameric capsid. Cyclosporine washout assays in Jurkat 
CD4+ T cells expressing engineered human TRIMCyp showed that C‑A1 causes faster and greater escape from TRIM‑
Cyp restriction. Sub‑cellular fractionation showed that small amounts of capsid accumulated in the nuclei of infected 
cells and C‑A1 reduced the nuclear capsid. A105S and N74D capsid mutant viruses did not accumulate capsid in the 
nucleus, irrespective of C‑A1 treatment. Depletion of Nup153, a nucleoporin located at the nuclear side of the nuclear 
pore that binds to HIV‑1 capsid, made the virus less susceptible to TRIMCyp restriction, suggesting that Nup153 may 
help maintain some integrity of the viral core in the nucleus. Furthermore C‑A1 increased binding of CPSF6, a nuclear 
protein, to capsid.
Conclusions: Our results indicate that capsid is involved in post‑nuclear entry steps preceding integration.
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Background
Early post-entry events in the HIV-1 life cycle are still 
poorly understood, yet they may reveal important host–
pathogen interactions and provide novel therapeutic tar-
gets. Following HIV-1 entry into cells, capsid proteins are 
shed from the conical core, a step called uncoating, and 
the viral RNA genome is reverse transcribed into a dou-
ble stranded DNA molecule. Although different models 
have been proposed [1, 2], a consensus is emerging based 
on biochemical, microscopy and genetic approaches sug-
gesting a stepwise uncoating of the viral core along with 
reverse transcription and intracellular trafficking [3–10]. 
Interestingly, uncoating has been shown to influence 
the early steps of HIV-1 infection. For example, certain 
mutations in the capsid protein (E45A, R132A, Q219A), 
which perturb core stability, impair reverse transcription 
[3]. Capsid Mutations Q63/Q67A and T54A/N57A show 
delayed uncoating and are defective in nuclear import 
and integration [11–13]. Some capsid mutations promote 
autointegration of the viral genome [14] whereas other 
changes in capsid or Gag alter the distribution of HIV-1 
integrations sites [15, 16].
It is not always clear how capsid impacts on such 
steps. In some cases, capsid mutations prevent binding 
to specific host factors such as CPSF6 and nucleoporin 
Nup153 [17–23]. In other cases, the intrinsic stability 
of the viral core may be changed. Yet we detected low 
amounts of HIV-1 capsid inside nuclei of infected CD4 T 
cells [24], an observation later confirmed and extended 
by several groups [25–27], suggesting a more direct 
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role for capsid in post-nuclear entry steps. Supporting 
this notion, capsid was shown to bind to nucleoporins 
Nup153 [18, 19, 22, 28] and Nup358, via the CypA bind-
ing domain [15, 29, 30], although the relevance of this 
interaction remains unclear [31]. Depletion of Transpor-
tin 3 (TNPO3), a nuclear transport receptor, impinges 
on both pre- and post-nuclear entry steps of HIV-1 and 
its effects map to capsid and host factor CPSF6 [21, 23, 
24, 32–35]. It has been proposed that TNPO3 stimulates 
a nuclear uncoating step that promotes integration [24]. 
Recently, capsid was shown to be the target of a novel 
post-nuclear entry restriction to SIV infection [36] and 
to permit greater access of the HIV-1 PIC deeper into 
the nuclei [27]. Furthermore, by binding to CPSF6, 
capsid directs HIV-1 integration into transcriptionally 
active chromatin regions [37]. However the sequence of 
post-nuclear entry events dependent on capsid remain 
largely unknown.
Several small molecules that inhibit HIV-1 infection 
by targeting capsid have been described [38–45]. At 
least three of these molecules impair the early stages of 
the viral life cycle: PF-74, BI-1 and C-A1. PF-74 inhibits 
reverse transcription at high doses (>10 μM), possibly by 
inducing destabilization of the capsid core and prema-
ture uncoating [18, 23, 39, 46]. At lower doses (<8 μM), 
PF-74 is a competitive inhibitor of CPSF6 and Nup153 
interaction with capsid [18, 28] and appears to act post-
nuclear entry [26]. BI-1, which binds to capsid in a differ-
ent mode, appears to stabilize the HIV-1 core, inhibiting 
nuclear transport of HIV-1 PICs without altering reverse 
transcription [18, 40] although there is also evidence 
that BI-1 might destabilize the core by competing with 
CPSF6 [47]. C-A1 is an antibiotic targeting gyrase B 
[48], which also impairs HIV-1 integration by an unde-
fined mechanism [38]. Here we show that C-A1 impairs 
HIV-1 integration in a capsid-dependent way without 
affecting reverse transcription. C-A1 lowers the amount 
of capsid detected in the nuclei and at the same time pro-
motes binding of CPSF6, a nuclear protein, to capsid. We 
also found that, similar to C-A1, depletion of Nup153 
promotes greater rescue from restriction mediated by 
TRIMCyp. Our data suggest that capsid is function-
ally important for events preceding integration and that 
completion of HIV-1 uncoating may take place inside the 
nucleus.
Results
C‑A1 inhibits HIV‑1 integration
We previously reported that C-A1 inhibited HIV-1 inte-
gration [38]. To confirm this finding, we infected Jurkat 
CD4+ T cells with a single cycle VSV-G pseudotyped 
HIV-1 vector expressing GFP (HIV-1GFP) in the pres-
ence of increasing concentrations of C-A1. Cells were 
infected at an MOI of 0.05–0.1 then analyzed by FACS 
and Taqman qPCR at 24 h and 10 days post-infection (for 
integrated provirus). C-A1 significantly inhibited HIV-1 
infection in a dose dependent way with an IC50 of 1 μM, 
however it did not affect reverse transcription or synthe-
sis of 2LTRs circular DNA forms, a hallmark of nuclear 
entry [49] (Fig.  1a). In contrast, C-A1 reduced HIV-1 
integration as measured by Taqman Alu-qPCR (Fig. 1a). 
We also fractionated cells infected with HIV-1GFP in the 
presence or absence of 3  μM C-A1 and measured the 
amount of viral DNA in the cytoplasmic and nuclear 
fractions. In agreement with previous results [50], viral 
DNA was mostly nuclear 16  h post-infection and C-A1 
did not change its distribution (Fig.  1b). DNA Topoi-
somerase II, a nuclear protein, and Na/K ATPase, a cyto-
plasmic and membrane protein, were used as markers of 
successful fractionation [24] (Fig. 1c).
We performed time of addition assays to evaluate 
by a different method the step of the HIV-1 life cycle 
blocked by C-A1. The rationale behind this assay is that 
the compound cannot block a step of the viral life cycle 
if added after the step has been completed. Inhibitors of 
reverse transcription and integration were used in par-
allel to define the temporal dynamics of each step [51]. 
Drugs were added at the indicated time point after infec-
tion, removed after 30 h and cells analysed by FACS 24 h 
later. This assay did not detect the effect of C-A1 on viral 
gene expression, which is reversible [38]. The reverse 
transcription inhibitor nevirapine started losing activity 
when added 4–6 h post-infection. The integration inhibi-
tor Raltegravir [52] and C-A1 both started losing activity 
when added 8 h post-infection (Fig. 1d), confirming that 
C-A1 inhibits HIV-1 at the integration step.
To test if the effect of C-A1 was capsid-specific, we 
used a virus bearing the A105S capsid mutation. This 
capsid mutation was selected after passaging HIV-1 in 
the presence of C-A1 and conferred resistance to the 
drug when introduced into HIV-1 NL4.3 [38]. In parallel, 
we also tested the N74D mutation, which confers partial 
resistance to the small compound PF-74 [39]. A105S and 
N74D capsid mutants were both resistant to the integra-
tion block mediated by C-A1 (Fig.  1e). Taken together, 
these results demonstrated that C-A1 blocks HIV-1 inte-
gration in a capsid-specific way.
C‑A1 interacts with HIV‑1 capsid
The results shown in Fig. 1 strongly suggested that cap-
sid is the primary target of C-A1. To examine this notion 
further, we performed molecular docking using the newly 
described native and hydrated hexameric HIV-1 capsid 
structure bound to PF-74 (4XFZ.pdb) [53]. This structure 
is well resolved in the region of helices 8 and 9 (H8/H9), 
where PF-74 binds, and it is in the open conformation, 
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making it much better suited for docking of C-A1. We 
identified an extended binding pocket bounded by two 
adjacent monomers from the same hexameric ring struc-
ture using the Compute: SiteFinder option in MOE [54]. 
C-A1 docked at the site although most poses had one pyr-
role exposed to solvent with minimal contacts with the 
protein. The C-A1-binding groove identified was similar 
but more extended than the binding site for PF-74 [39], 
BI-1 [40] and a CPSF6 peptide [18, 28, 40]. The groove 
is formed by both capsid subunits and includes Asn53, 
Asn57, Gln63, Lys70, Thr107 and Gln112 of subunit A, 
and Glu128, Arg173, Gln179, Lys182 of subunit B (Fig. 2; 
Additional file 1: Fig. S1). PF-74 occupies a smaller region 
of the cleft delimited by Asn57, Gln63, Lys70 and Thr107 
of the A subunit and Arg173, Gln179 and Lys182 of the B 
subunit (Fig. 2; Additional file 1: Fig. S1).
The A105S and N74D mutations confer resistance to 
C-A1, suggesting that these residues are important for 
a
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Fig. 1 C‑A1 inhibits HIV‑1 integration and capsid mutations confer resistance to the drug. a Jurkat cells were infected with HIV‑1GFP at an MOI of 
0.05–0.1 in the presence of the indicated concentrations of C‑A1 and analyzed by FACS 24 h later to determine the percentage of infected cells, the 
amount of viral DNA and 2LTR circular DNA. The amount of integrated viral DNA was determined by Alu‑LTR TaqMan qPCR 10 days post‑infection. 
b Jurkat cells were infected with HIV‑1GFP at the same MOI in the presence or absence of 3 μM C‑A1 and fractionated into a cytoplasmic and a 
nuclear fraction 16 h post‑infection. The amount of viral DNA was measured by TaqMan qPCR in each fraction. c The quality of the fractionation 
was assessed by Western blot to detect DNA Topoisomerase II (Topo II) and Na/K ATPase (ATPase); representative of three experiments. d Time of 
addition assay. Jurkat cells were infected with HIV‑1GFP at an MOI of 0.1 and the compounds were added at the indicated time points after infection 
(time 0). Cells were analyzed by FACS 36 h post‑infection. e Jurkat cells were infected with HIV‑1GFP WT, A105S or N74D capsid mutants at an MOI of 
0.1 in the presence of 3 μM C‑A1 and the quantity of integrated viral DNA was measured by Alu‑LTR TaqMan qPCR 1 week post‑infection. Average 
values ±SD of three independent experiments are shown in (a, b, e)
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the antiretroviral effect of the drug. Ala105 is partially 
buried by Thr107 so direct contact with CA-1 is not 
observed (Fig. 2; Additional file 1: Fig. S1), but as this is 
a pinch-point in the binding groove, any mutation to a 
larger amino acid will restrict space in this region, pre-
sumably reducing the binding affinity of C-A1 (Fig.  2). 
Alternatively, such mutations may exert an indirect effect 
by changing the way C-A1 binds to capsid or abolishing 
binding to host-cofactors [20].
To test more directly the molecular docking predic-
tions, we performed isothermal titration calorimetry 
(ITC) using disulphide linked HIV-1 CA hexamers. These 
data (Fig. 3) reveal that C-A1 binds to hexameric CA with 
a stoichiometry of 1 CA-1 per CA monomer and with a 
dissociation constant (Kd) of 220  nM, comparable with 
90 nM observed for the PF74–hexamer interaction.
C‑A1 decreases sensitivity to TRIMCyp in CD4+ T cells
The C-A1 binding pocket in capsid is important for cor-
rect CA–CA intermolecular interactions and formation 
of the hexameric lattice that defines the mature HIV-1 
core [55]. We hypothesized that C-A1 might perturb 
uncoating of the viral core, either by inducing its prema-
ture disassembly or by stabilizing it. To test this hypoth-
esis, we performed cyclosporine (CsA) washout assays 
[4, 5, 56, 57]. This assay exploits the restriction factor 
TRIMCyp, which targets capsid directly at the cyclophi-
lin A (CypA) loop, blocking infection [58]. In TRIMCyp 
expressing cells, HIV-1 is restricted but addition of CsA 
prevents TRIMCyp binding to capsid. CsA is added at 
the time of infection to prevent TRIMCyp restriction 
and then is removed at different time points. The effect 
of CsA is reversible so when the drug is removed, TRIM-
Cyp is again able to restrict infection, as long as enough 
capsid proteins remain associated with the reverse tran-
scription complex (RTC). Because CsA is removed at dif-
ferent time points, it is then possible to estimate when, 
in the course of infection, enough capsid has been shed 
such that TRIMCyp can no longer restrict the virus 
(Additional file 2: Fig. S2) [59]. In other words, this assay 
indirectly measures loss of capsid by determining for how 
long the virus remains susceptible to TRIMCyp restric-
tion. We, and others, interpret the loss of TRIMCyp 
restriction over time as “uncoating” [5, 57]. Though indi-
rect, the CsA washout assay has the advantage of detect-
ing infectious or productive events rather than the bulk 
of the viral population and has been successfully used 
to measure the kinetics of HIV-1 uncoating in OMK 
cells, which naturally express TRIMCyp, and HeLa cells 
expressing OMK TRIMCyp [5, 57]. However the kinet-
ics of HIV-1 uncoating appear to be cell type dependent 
[4], hence we have adapted the assay in CD4+ Jurkat T 
cells stably expressing an engineered form of the human 
TRIM5α protein fused with CypA at position S322 
(T5Cyp) or a mutant version that does not bind to capsid 
and cannot restrict infection (H126Q) [60].
To establish the CsA washout assays in these cells, 
titrations were conducted first to determine the linearity 
of the signal. Cells were infected with increasing amounts 
of HIV-1GFP and analysed by FACS 48 h later. T5Cyp cells 
showed a 10-fold restriction compared to H126Q cells 
with an almost linear dose–response curve within the 
0.3–3 % infection range (T5Cyp cells) or 0.5–19 % range 
(H126Q) (Additional file  3: Fig.  S3). The same results 
were obtained with N74D and A105S HIV-1GFP (Addi-
tional file  3: Fig.  S3). Therefore these Jurkat cells were 
infected at a low MOI (0.01–0.03) to prevent saturation 
of T5Cyp and maintain linearity of the readout.
Next, we tested the ability of CsA to rescue infection. 
To this end, T5Cyp and H126Q cells were infected in par-
allel with a fixed amount of HIV-1GFP in the presence of 
increasing concentrations of CsA. In H126Q cells, CsA 
weakly inhibited infection whereas in T5Cyp cells it 
rescued infection at concentrations >0.6  μM reaching a 
plateau at about 1.25  μM (Additional file  3: Fig.  S3). By 
gating on the live cell population, it was found that CsA 
started to be toxic at concentrations >1 μM (Additional 
file 3: Fig. S3). Therefore, it was decided to use 1 μM CsA 
in the assay, which afforded good rescue of infection 
without toxicity.
Preliminary CsA washout assays were carried out as 
described in Additional file  2: Fig.  S2. TRIMCyp and 
H126Q cells were infected on ice with HIV-1GFP virus 
(at an MOI 0.01–0.03) in the presence of 1  μM CsA 
or 3  μM C-A1. Cells were then spinoculated at 4  °C to 
Fig. 2 Molecular docking of C‑A1 (in yellow) in HIV‑1 hexameric 
capsid structure 4XFZ.pdb with bound PF‑74 (in green) using the 
Compute: SiteFinder option in MOE software. A single C‑A1 confor‑
mation is shown bound to capsid. The two subunits of capsid are 
depicted in brown and turquoise respectively. The position of key 
residues is indicated
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synchronize infection and CsA was removed by media 
change at different time points (0, 1, 2, 3, 4, 6 and 8  h 
after spinoculation). The percentage of infected GFP+ 
cells was measured by FACS 48  h later. Approximately 
70  % cells were alive as determined by gating on the 
untreated population.
Neither CsA nor C-A1 significantly affected the lev-
els of infection over time in control H126Q cells (Addi-
tional file 4: Fig. S4), which was expected because C-A1 
was washed out early hence could not inhibit infection 
on its own. In contrast, CsA significantly rescued infec-
tion in T5Cyp cells and the rescue effect was greater at 
later washout time points (Additional file 4: Fig. S4). This 
was consistent with the notion that CsA protected more 
viruses from TRIMCyp restriction if removed at a later 
time point. C-A1 on its own did not rescue infection. An 
extended assay showed that the rescue of infection medi-
ated by CsA reaches a plateau at about 10 h (Additional 
file 3: Fig. S4), suggesting that, by that time, most virions 
probably were no longer sensitive to TRIMCyp, making 
CsA irrelevant.
CsA washout assays were then performed with wild 
type (WT) or capsid mutant N74D and A105S HIVGFP 
vectors to control for specificity. Infection levels, 
expressed as percentage of GFP+ cells, were measured 
for each time point by FACS and plotted using the soft-
ware XLfit (ID Business Solutions Ltd.) to calculate the 
point at which 50 % infection levels were reached, rela-
tive to the 8 h time point (Fig. 4a). This is the point where 
50 % RTC lose susceptibility to T5Cyp because produc-
tive infection takes place even if CsA is washed out. This 
point is hereafter called “the half-time of uncoating” or 
ToU50. The expectation is that if CA is shed faster from 
the RTCs, the ToU50 will be smaller whereas a greater 
ToU50 indicates slower uncoating. Data from four inde-
pendent experiments were collected: the average ±SEM 
ToU50 for WT HIV-1GFP was 110  ±  16  min, for the 
N74D virus was 88  ±  16  min and for the A105S virus 
was 92  ±  31  min (Fig.  4b). This is longer than ToU50 
observed in OMK cells (40–70  min) [5], which may be 
due to the cell type used in our assays. Upon addition 
of C-A1, the ToU50 of WT HIV-1GFP was significantly 
shortened to approximately 34 ± 17 min, whereas ToU50 
appeared higher for N74D (151  ±  23  min) and A105S 
(122 ±  40 min) viruses, although the difference did not 
reach statistical significance (Fig.  4b). These data indi-
cated that C-A1 makes the virus less susceptible to 
TRIMCyp, possibly by accelerating the loss of capsid in 
infected cells. This effect was dependent on specific tar-
geting of CA.
Fig. 3 Analysis of drug–CA interactions. The interaction of C‑A1 (a) and PF‑74 (b) with HIV‑1 CA hexamers was quantified by ITC. The top panels 
show raw thermograms and the bottom panels show the titration data along with best line of best fit and the fitted parameters (inset)
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Fig. 4 C‑A1 reduces sensitivity to T5Cyp in CD4+ T cells. a CsA washout assays were performed on Jurkat cells stably expressing T5Cyp. Cells were 
infected with HIV‑1GFP WT, N74D or A105S mutants in the presence of 1 μM CsA alone or in combination with 3 μM C‑A1. The drugs were washed 
out at the indicated time points and cells analyzed by FACS 48 h post‑infection to calculate the percentage of infected (GFP+) cells. Some back‑
ground infection was detected after spinoculation hence values on the Y‑axis do not start at 0. Data were plotted using XLfit to determine the half 
time of uncoating (ToU50). The representative ToU50 of six experiments is shown (red dashed line). b Plot showing average values of ToU50 ± SEM of 
four independent experiments. Each dot on the graph represents an independent experiment (note that five experiments were carried out with the 
A105S mutant virus). *p < 0.02, statistical significance was calculated using Student’s unpaired, two‑tailed t test
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C‑A1 reduces accumulation of capsid into the nucleus
We returned to the issue of nuclear capsid and integra-
tion. We reasoned that C-A1, by stimulating uncoating, 
should reduce the amount of nuclear capsid associated 
with the PIC, which may affect integration. Thus we 
examined if C-A1 affected the distribution of capsid 
in the nucleus and cytoplasm of acutely infected Jurkat 
cells. Cells were infected with HIV-1GFP at an MOI of 0.5 
in the presence or absence of C-A1 and 16 h later frac-
tionated into nuclear and cytoplasmic extracts, which 
were analyzed for the presence of capsid by Western 
blot (Fig. 5a). C-A1 had no effect on the overall amount 
of HIV-1 capsid detected in the cytoplasm, however it 
reduced nuclear accumulation of capsid and this effect 
was reproducible (Fig. 5b–c). The A105S and the N74D 
mutant viruses did not show significant accumulation of 
capsid into the nucleus, with or without C-A1, indicating 
that such viruses shed almost all of their capsid before 
nuclear entry (Fig. 5).
Depletion of Nup153 affects sensitivity to T5Cyp
We sought further evidence that capsid in the nucleus 
was associated with a functional PIC and opted to exploit 
Nup153 for this purpose.
Nup153 has three domains, an-N-terminal domain that 
anchors it to the nuclear ring region of the NPC, a central 
domain that contains four zinc-fingers regions and C-ter-
minal domain that is rich in FG repeats [61–63]. Nup153 
is located on the nuclear side of the nuclear envelope 
[61–65] and its N-terminal domain interacts with Nup50 
[66], located at the nuclear basket, and Tpr, forming 
the nuclear filaments [67]. The C-terminal domain of 
Nup153 is flexible and it is sometimes observed stretch-
ing towards the cytoplasmic face of the NPC [68]. 
Nup153 binds to HIV-1 capsid and has been proposed 
to modulate uncoating and integration [19, 22]. Given its 
intranuclear localisation and its ability to bind to hexam-
eric HIV-1 CA, we decided that Nup153 would be a good 
tool to investigate if functional nuclear PICs contain CA. 
To this end, we decided to perform CsA washout assays 
in cells depleted of Nup153. If Nup153 promotes virus 
uncoating at the NPC, then its depletion should result in 
more capsid bound to the virus and greater susceptibil-
ity to TRIMCyp restriction. In contrast, if Nup153 helps 
maintaining capsid at the viral core, its depletion should 
result in more shedding of capsid and lower susceptibility 
to TRIMCyp restriction (greater rescue of infection).
First, we tested if TRIMCyp can be detected in the 
nucleus, similar to TRIM5α [69]. We generated Jurkat 
cells stably expressing a C-terminus Flag-tagged TRIM-
Cyp, which potently restricted HIV-1 infection (Fig. 6a). 
In these cells we also depleted Nup153 by shRNA 
and performed cell fractionation. Nup153 was mostly 
nuclear (Fig.  6b upper panel) although some Nup153 
was detected in the cytoplasm, presumably due to small 
amounts of nuclear envelope contaminating the cytoplas-
mic fractions (Fig. 6b upper panel). TRIMCyp was mostly 
present in the cytoplasm, however TRIMCyp could also 
be detected in the nucleus in both control and Nup153 
KD cells (Fig.  6b). The quality of the fractionation was 
confirmed by the distribution of Nup153, DNA Topo II 
and Na/K ATPase (Fig. 6b, lower two panels).
Second, we investigated the presence of nuclear cap-
sid in T5Cyp cells depleted of Nup153. T5Cyp cells 
were infected in the presence of CsA, fractionated and 
examined by Western blot to detect capsid (Fig.  6c). In 
cells infected with WT virus, small amounts of capsid 
were detected in the nuclei of both control and Nup153 
KD cells, albeit in Nup153 depleted cells the overall sig-
nal was weaker (Fig. 6c). In cells infected with the N74D 
virus, virtually no capsid was detected in the nuclei, irre-
spective of Nup153.
Having established that both restriction factor (TRIM-
Cyp) and target (capsid) are detectable in the nuclei, we 
performed CsA washout assays (Fig. 6e, Additional file 5: 
Fig. S5). Depletion of Nup153 added an additional block 
to HIV-1 infection on top of T5Cyp-mediated restriction 
Fig. 5 C‑A1 reduces accumulation of capsid into the nucleus of 
infected cells. a Jurkat cells were infected at an MOI of 0.5 with HIV‑
1GFP WT, A105S or N74D mutants in the presence or absence of 3 μM 
C‑A1. Cells were fractionated 16 h post‑infection and the distribu‑
tion of capsid, Na/K ATPase and DNA Topoisomerase II (Topo II) in 
the nucleus and cytoplasm examined by Western blot. b The ratio 
of cytoplasmic versus nuclear capsid was calculated using ImageJ 
and normalized for Na/K ATPase (cytoplasmic fraction) or TopoII 
(nuclear fraction). Average values ±SD of at least four independent 
experiments are shown for WT virus and three experiments for N74D 
or A105S viruses. c Fold change in the cytoplasmic/nuclear ratio of 
capsid based on ImageJ quantification. Statistical significance was 
calculated using Student’s unpaired, two‑tailed t‑test
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(Additional file  5: Fig.  S5) but, notably, resulted in a 
greater rescue of infection relative to control DsRed 
KD cells [50] (Fig.  6e, Additional file  5: Figure  S5). As 
such, the fold rescue of infection, measured as the ratio 
between infection levels in the presence or absence of 
CsA, was higher in Nup153 KD cells compared to DsRed 
Fig. 6 Depletion of Nup153 affects sensitivity to T5Cyp in CD4+ T cells. a Jurkat cells stably expressing a Flag‑tagged TRIMCyp or an empty vector 
(Ctr) were infected with increasing doses of HIV‑1GFP and analyzed by FACS 48 h later. b Cells stably expressing TRIMCyp were depleted of Nup153 
using shRNA. Cells were fractionated into nuclear and cytoplasmic fractions and analyzed by Western blot to detect the distribution of TRIMCyp, 
Nup153, DNA Topo II and Na/K ATPase. Cyt cytoplasmic fraction, Nu nuclear fraction, Ctr‑, Jurkat cells not expressing TRIMCyp. c Cells depleted of 
Nup153 or control cells expressing an shRNA targeting the Discosoma corallimorpharian mRNA (dsRed) were infected with HIV‑1GFP at an MOI of 
0.1 in the presence of CsA, fractionated into nuclear and cytoplasmic fractions and analyzed by Western blot to detect the distribution of capsid, 
DNA Topo II and Na/K ATPase. d Nup153 was depleted by shRNA in T5Cyp cells. An shRNA targeting DsRed (DsR) was used as control. e These cells 
were used to perform CsA washout assays upon infection with HIV‑1GFP WT or capsid mutant N74D. Cells were analyzed by FACS 48 h post‑infection 
and the fold rescue of infection induced by CsA was plotted. Depletion of Nup153 enhanced rescue of infection significantly in T5Cyp cells and the 
effect was specific for HIV‑1GFP WT. Average values of rescue of infection ±SD are shown for three independent experiments
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KD T5Cyp cells (Fig.  6e). Furthermore, rescue of infec-
tion was clearly capsid-specific because it could not be 
detected with the N74D virus, which indeed showed no 
nuclear capsid upon cell fractionation (Fig. 6e, Additional 
file 5: Figure S5). This suggested that, in Nup153-depleted 
cells, more RTC/PICs escaped T5Cyp restriction thus 
Nup153 may help stabilize what is presumably a partially 
disassembled core navigating the NPC. These results also 
indicated that nuclear capsid is associated with func-
tional PICs, which can be targeted and inactivated by 
T5Cyp.
C‑A1 promotes CPSF6 binding to HIV‑1 capsid cores
The host factor CPSF6 is known to bind hexameric capsid 
both in  vitro and in cells and influence HIV-1 infection 
[17, 18, 20, 21, 23, 28, 47, 70]. In physiological conditions, 
CPSF6 is a nuclear protein, which participates in cellu-
lar RNA processing (mainly poly site selection cleavage 
and polyadenylation) [71] and may guide the PIC towards 
active regions of chromatin [27]. Given that C-A1 binds 
to a cleft in capsid that in part overlaps with the CPSF6 
binding site, we asked if C-A1 affected CPSF6 binding 
to capsid. We performed pull down assays by combin-
ing in vitro assembled CA–NC tubes and extracts from 
cells expressing Flag-tagged CPSF6. Remarkably, C-A1 
increased CPSF6 binding to cores in a dose-depend-
ent manner, whereas PF-74 showed the opposite effect 
(Fig.  7a, b), in agreement with previous reports [18, 28, 
47]. These results suggested that C-A1 likely perturbs 
nuclear events regulated by both CPSF6 and capsid, 
resulting in an integration defect.
Discussion
We previously suggested that C-A1 targeted capsid 
because serial passaging of HIV-1 in the presence of the 
drug resulted in the emergence of a drug-resistant virus 
with the A105S capsid mutation. This point mutation was 
necessary and sufficient to confer full resistance to the 
integration block mediated by C-A1 [38]. We have now 
provided strong evidence that C-A1 targets capsid. We 
identified another capsid point mutation, N74D, confer-
ring resistance to C-A1. Molecular docking analysis iden-
tified a large cleft in the hexameric capsid structure where 
C-A1 was predicted to bind. ITC demonstrated that 
C-A1 binds to hexameric capsid with a Kd of 220  nM, 
which compares well with 90 nM observed for the PF74–
hexamer interaction. Collectively, the data support the 
notion that C-A1 binds to hexameric capsid. Moreover, 
although, we have employed computational modelling 
and a co-crystal structure will ultimately be required to 
demonstrate the mode of C-A1 binding to capsid, our 
biochemical and biophysical data do support the notion 
for a CA-1 interaction that requires contributions from 
more than one monomer in the hexamer as is observed 
with CPSF6, Nup153 and PF-74 [18, 28].
It is intriguing how novel inhibitors of Hepatitis C virus 
replication have a symmetric chemical structure, similar 
to C-A1. Such inhibitors are also predicted to bind to a 
large cleft in the C-terminal domain of NS5A protein and 
perturb its dimerization [72]. Hence large and symmet-
ric compounds such as C-A1 may provide a general plat-
form to perturb dimerization or oligomerization of viral 
proteins.
C-A1 inhibits HIV-1 integration, which led us to 
explore the possible functional relationship between cap-
sid and integration. We proceeded in a stepwise fashion 
by investigating the effect of C-A1 on capsid uncoating, 
nuclear accumulation and binding to CPSF6.
The activity of C-A1 was tested in cellulo by the CsA 
washout assay. To our knowledge, we were the first to 
perform CsA washout assays in CD4+ T cells stably 
expressing an engineered human TRIMCyp. We went 
to some length to establish the assay in CD4+ T cells 
because of their relevance for HIV-1 infection. The assay 
was successfully established, although working with sus-
pension cells meant that analysis of very early time points 
(between 15  min and 1  h) was not possible. Repeated 
centrifugations to washout the drugs at very early time 
points prevented infection above background (not 
shown) and a minimum of 1 h incubation with the virus 
was necessary. Although we lost such early time points in 
our assay, HIV-1 uncoating in T cells has been reported 
to take hours rather than minutes [4]. In our assay we 
found that C-A1, in combination with CsA, reduces 
the sensitivity of HIV-1 to T5Cyp restriction. Because 
restriction depends on direct binding of T5Cyp to the 
CypA loop of HIV-1 capsid, the simplest interpretation 
of the results is that loss of restriction is caused by a loss 
of capsid, or uncoating. We exclude that C-A1 directly 
or indirectly inactivated T5Cyp because addition of the 
drug alone did not rescue HIV-1 infection in T5Cyp 
cells. We found that the ToU50 for HIV-1 in Jurkat cells 
was about 110 min, which is somewhat longer than the 
ToU50 reported in HeLa and OMK cells (40–70 min) [5, 
57], however kinetics of uncoating are cell type depend-
ent and slower in CD4+ T cells [4].
By performing cellular fractionation, we examined the 
downstream consequences of greater capsid disassembly 
induced by C-A1. We detected less capsid inside, or asso-
ciated with, the nuclei of C-A1 treated cells compared to 
untreated cells. Two scenarios may explain this observa-
tion. Either free capsid proteins shed from the RTC/PIC 
reached the nuclei and were degraded faster than in the 
cytoplasm, or PICs in the nuclei contained less capsid fol-
lowing treatment with C-A1. We prefer the second pos-
sibility, which would be more consistent with previous 
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genetic and imaging results implicating capsid in post-
nuclear entry steps [24–27, 73]. However, the hypothesis 
that capsid remained associated with functional PICs in 
the nucleus required further validation.
To test this notion, we used the CsA washout assay 
in cells depleted of Nup153. The assay measures func-
tional PICs, and the nuclear location of Nup153 means 
that any change in the susceptibility to T5Cyp restriction 
is likely to occur in the nucleus or at the nuclear side of 
the NPC. Post-nuclear entry restriction is not unprec-
edented. Fusion between the restriction factor Fv-1 and 
CypA resulted in chimeric proteins that maintained their 
specific ability to target capsid yet they restricted HIV-1 
at post nuclear entry steps [74, 75]. Recently, a capsid-
specific restriction of SIV infection was also shown to be 
post-nuclear entry [36].
We confirmed that depletion of Nup153 reduced 
HIV-1 infection in T5Cyp cells [30, 76]. Unexpectedly, we 
also found that depletion of Nup153 induced greater res-
cue of HIV-1 from T5Cyp restriction, suggesting that loss 
of Nup153 led to a greater loss of capsid. Thus Nup153 
appears to stabilise capsid on functional PICs. The N74D 
mutant virus remained insensitive to Nup153 depletion, 
presumably because it had already lost almost all capsid 
by the time it entered the nucleus. Overall, the results 
supported the notion that capsid remains associated with 
functional PICs in the nuclear fraction. Some caution is 
required, however, because depletion of Nup153 might 
affect the nucleocytoplasmic distribution of host factors 
that stabilize, or destabilize, the viral core. Furthermore, 
depletion of Nup153 may result in the loss of Nup98 and 
Nup93 from the nuclear basket of the NPC [63], which 
may also indirectly affect HIV-1 capsid.
Regardless if Nup153 has a direct or indirect effect 
on core stability, we might need to reconsider some of 
the early steps of the HIV-1 life cycle: it was assumed 
that HIV-1 uncoating starts early post-infection and is 
completed well before the PIC enters the nucleus [77]. 
Although recent evidence confirmed that shedding of the 
capsid does indeed start early post-infection [27, 73, 78], 
uncoating may be completed after PIC nuclear entry [24]. 
This would fit with our recent data suggesting that the 
Fig. 7 C‑A1 enhances capsid binding to CPSF6. a Cellular extracts expressing CPSF6‑FLAG were incubated with in vitro assembled HIV‑1 CA–NC 
complexes at room temperature for 1 h in the presence of C‑A1 or PF74. The mixtures were applied onto a 70 % sucrose cushion and centrifuged. 
INPUT represents the mixtures before being applied to the 70 % cushion. The INPUT was Western blotted using anti‑FLAG antibodies. The pellet 
from the 70 % cushion (BOUND) was analyzed by Western blotting using anti‑FLAG and anti‑capsid antibodies. The results of three experiments 
were similar and standard deviations are shown. b Similar binding experiments were performed using increasing concentrations of C‑A1. The results 
of three experiments were similar
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biophysical properties of the NPC barrier ensures that 
large cargos, such as the PIC, are efficiently transported 
across the pore provided that enough contact surface is 
available on the cargo to tip the fine-tuned Nup–Nup 
interactions and make the barrier permeable [79]. In 
this respect, capsid, which binds to Nups, may have an 
important, yet unappreciated, function.
How then can C-A1 affect integration? If capsid is 
required for efficient integration, the drug might act by 
reducing capsid associated with nuclear PICs. However 
this hypothesis is not fully convincing because viruses 
harboring the A105S and N74D mutations are insensi-
tive to C-A1, they do not show accumulation of capsid in 
the nucleus yet they are capable of integrating. To clarify 
this issue, we tested the effect of C-A1 on the interaction 
between capsid and CPSF6. Remarkably, C-A1 stimulated 
binding of CPSF6 to capsid in a dose dependent way. It is 
presently unclear how C-A1 might enhance capsid bind-
ing to CPSF6 given that the C-A1 binding cleft is pre-
dicted to partly overlap with that one of PF-74 and BI-1. 
However C-A1 is a large and flexible molecule, which 
might fold to cross-link CPSF6 to capsid, given also that 
one of its pyrrolic rings may be exposed to solvent hence 
may be available for additional interactions.
We highlight the fact that CPSF6 is a nuclear protein 
in physiological conditions, and that tiny amounts of 
CPSF6 are detected in the cytoplasm only in cells lacking 
TNPO3 [21, 27]. Thus our results suggest that C-A1 may 
prevent capsid dissociation from CPSF6 in the nucleus. 
CPSF6 is known to stabilise the HIV-1 capsid core [21, 
23] hence C-A1 may tether the PIC to CPSF6 negating 
further movement or maturation. This scenario would 
nicely explain why mutant viruses that shed their capsid 
before nuclear entry are insensitive to C-A1: they would 
not be tethered to CPSF6.
In conclusion, we propose a model that integrates the 
results presented here and recent data in the literature 
(Fig.  8). HIV-1 starts uncoating in the cytoplasm and at 
the nuclear pore. A partially disassembled core is trans-
ported across the nuclear pore, reaching the nuclear 
basket. Here, Nup153 helps maintain the PIC struc-
ture, which is translocated onto chromatin domains rich 
in active RNA processing by binding to CPSF6. These 
domains are often found in proximity of the nuclear 
pores [80, 81]. There, uncoating is completed, possibly by 
TNPO3 [24]; capsid and CPSF6 are dissociated from the 
PIC, which binds to LEDGF to integrate in proximity of 
actively transcribed genes. C-A1 perturbs this sequence of 
events by inducing greater uncoating and by affecting the 
PIC structure bound to Nup153. When the PIC is trans-
located onto active chromatin domains, capsid cannot 
properly dissociate from CPSF6 such that the PIC remains 
tethered and is unable to proceed to integration. This 
model is consistent with published imaging data showing 
that nuclear PICs contain capsid, which associates with 
CPSF6 inside the nuclei [27] and with data showing that 
capsid is important to target HIV-1 integration into active 
chromatin regions by binding to CPSF6 [37]. Mutant 
viruses N74D and A105S proceed through a capsid-inde-
pendent pathway, which makes them insensitive to C-A1. 
However such mutant viruses do not occur in natural 
HIV-1 infections [82], suggesting that the capsid-depend-
ent way of integration may be important in vivo.
Conclusions
We conclude that the antibiotic Coumermycin-A1, by 
binding to HIV-1 capsid, perturbs the sequence of nuclear 
events leading to correct viral integration. We provide 
evidence for a post-nuclear entry step in the HIV-1 life 
cycle that can be targeted by a small molecule and define 
a new mechanism of action for Coumermycin-A1.
Fig. 8 Model of C‑A1 mode of action. (1) HIV‑1 uncoating in the 
cytoplasm and at the nuclear pore. (2) A partially disassembled core 
is transported across the nuclear pore, reaching the nuclear basket 
where Nup153 helps maintaining the PIC structure. (3) The PIC is 
delivered onto chromatin domains rich in actively transcribing genes 
by binding to CPSF6. Some of these domains are in proximity of the 
nuclear pores [80, 81]. Uncoating is completed, possibly by TNPO3; 
capsid and CPSF6 are dissociated from the PIC, which binds to LEDGF 
to integrate in proximity of genes. (4) C‑A1 perturbs this sequence 
of events by inducing greater uncoating and by affecting the PIC 
structure bound to Nup153 (5). When the PIC is delivered onto active 
chromatin domains, capsid cannot properly dissociate from CPSF6 
such that the PIC remains tethered and is unable to proceed to 
integration (6). Mutant viruses N74D and A105S proceed through a 
capsid‑independent pathway and are insensitive to C‑A1
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Methods
Chemical reagents
C-A1, PF-74 and CsA were purchased from Sigma and 
dissolved in DMSO at a final concentration of 5, 10 and 
42 mM respectively.
Docking studies
For identifying the binding cleft and initial docking 
of CA-1 the following software programs were used: 
FRED_receptor version 2.2.5 (2009) and FRED (Fast 
Rigid Exhaustive Docking) version 2.2.5 (2009) [Open 
Eye Scientific Software Inc., Santa Fe, NM 87507]. Sub-
sequent docking was carried using the docking module 
within MOE (version 2014.09) [Chemical Computing 
Group Inc., Montreal, Quebec, Canada] [83]. The crys-
tal complex 4XFZ.pdb was imported into MOE as 
a biological unit (i.e.; Symmetry biologic) giving the 
hexamer. The docking parameters used were: Force-
field—Amber10:EHT, Reaction Field for solvation, ini-
tial scoring London deltaG, refinement with BBV/WSA 
deltaG. A limited minimization of C-A1 and contacting 
side chains allowed H-bond partners to be fulfilled.
ITC
C-terminally His-tagged HIV-1 CA A14C/E45C/W184A/
M185A quadruple mutant was expressed in E. coli and 
purified by nickel affinity and gel filtration chromatogra-
phy. Cross-linked hexamers were produced as previously 
described [84] and then exhaustively dialysed against ITC 
buffer (20 mM sodium phosphate pH 7, 150 mM NaCl). 
Prior to ITC, PF-74 and C-A1 were dissolved at 10 mM 
in DMSO, diluted to their final concentrations (PF-74—
30 μM, C-A1—12 μM) in ITC buffer. The concentration 
of C-A1 in the experiment was confirmed by 1D 1H NMR 
through comparison of methyl resonances with those of 
a Trimethylsilyl propanoic acid standard reference. The 
monomer concentration of CA-hexamers was 390  μM 
for PF-74 and 120  μM for C-A1 titrations respectively. 
DMSO was also added to the hexamers to match the final 
DMSO concentration of the drug. ITC experiments were 
carried out at 293 K by titrating HIV-1 CA hexamers into 
the cell containing either C-A1 or PF-74 at 180 s intervals 
(3  μL injections for C-A1, 1.5  μL injections for PF-74). 
Heats of dilution for the hexamers were measured and 
subtracted from the titrations prior to data fitting. Bind-
ing isotherms were fitted to a single-site model using 
ORIGIN (MicroCal), where the hexamer concentration 
was expressed in terms of the monomeric equivalent.
Cells and viruses
293T cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco Labs, Paisley, UK) supple-
mented with 10  % foetal calf serum (FCS) (Helena 
Bioscience, Newcastle, UK) and 2 mM glutamine at 37 °C 
in 5  % CO2. Jurkat cells were grown in RPMI medium 
supplemented with 10 % FCS at 37 °C in 10 % CO2. HIV-
1GFP vectors were made and purified as described pre-
viously [50]. The A105S and the N74D mutation were 
introduced into pCMV∆R8.2 using the QuikChange 
II XL Kit (Stratagene) as previously described [24, 38]. 
Reverse transcriptase (RT) activity was measured by the 
Lenti-RT™ Activity Assay (Cavidi Tech, Uppsala, Swe-
den) following the manufacturer’s instructions. For infec-
tions, Jurkat cells were plated at 5 ×  105/mL in 48-well 
plates, infected with serial dilutions of HIVGFP and ana-
lysed by FACS at the indicated time points. For DNA 
analysis, Jurkat cells were plated at 5 × 105/mL in 6-well 
plates, infected at an MOI of 0.1 and DNA extracted 24, 
48 h and 10 days later.
qPCR
TaqMan qPCR was performed in an Eppendorf Realplex 
2000 thermocycler as described [85]. For amplification of 
GFP (-strand) primers sequence was forward 5′-CAACAG 
CCACAACGTCTATATCAT-3′, reverse 5′-ATGTTGT 
GGCGGATCTTGAAG-3′, probe 5′-FAM-CCGACAA 
GCAGAAGAACGGCATCAA-TAMRA-3′. For ampli-
fication of 2LTR circular DNA, the same conditions 
were used with primers 2LTRqPCRF: 5′-AACTA 
GAGATCCCTCAGACCCTTTT-3′ and 2LTRqPCRRC: 
5′-CTTGTCTTCGTTGGGAGTGAATT-3′ and probe 
5′-FAM-CTAGAGTTTTCCACACTGAC-0-TAMRA-3′ 
[50]. Standards were prepared by PCR amplification of 
DNA from acutely infected cells with primers 2LTRF 
5′-GCCTCAATAAAGCTTGCCTGG-3′ and 2LTRRC 
5′-TCCCAGGCTCAGATCTGGTCTAAC-3′. The ampli-
fication product was cloned into TOPO vector, ampli-
fied and confirmed by sequencing. Alu-LTR Taqman 
qPCR was carried out as previously described [38] using 
primers ALU-forward, AAC TAG GGA ACC CAC TGC 
TTA AG and LTR1-reverse, TGC TGG GAT TAC AGG 
CGT GAG (for first round amplification) and ALU-for-
ward AAC TAG GGA ACC CAC TGC TTA AG, LTR 
2-reverse, TGC TAG AGA TTT TCC ACA CTG ACT, 
ALU-probe, FAMRA—TAG TGT GTG CCC GTC TGT 
TGT GTG AC—TAM (for second round Taqman qPCR).
Depletion of Nup153
Nup153 was depleted using shRNA expressed from a len-
tiviral vector. ShRNA oligonucleotides sequences were as 
follows: Nup153 forward 5′-GATCCGCAATTCGTCT 
C A A G C AT TAT T C A A G A G ATA AT G C T T G A 
GACGAATTGTTTTTTACGCGTG-3′, reverse 5′-AATT 
C ACG CGTAAAAAAC AATTCGTC TC AAG C AT 
TAT C T C T T G A ATA AT G C T T G A G A C G A AT T 
GCG-3′. Control shRNA targeting DsRed [50] mRNA 
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was generated using the sequence: forward 5′-GATCC 
AAAAAGTAATGCAGAAGAAGACCATGGGCG 
AACCCATGGTCTTCTTCTGCATTAACGCGTG-3′, 
reverse 5′-AATTCACGCGTTAATGCAGAAGAAGA 
CCATGGGTTCGCCCATGGTCTTCTTCTGCATT 
ACTTTTTG-3′. Target and control DsRed oligonu-
cleotides were from Sigma-Aldrich. Annealing was per-
formed by incubation at 94  °C 30  s, 72  °C 2  min, 37  °C 
2  min, 25  °C 2  min. Annealed oligonucleotides were 
inserted to Bam HI/EcoR I digested pSIREN-HIV (Clon-
tech). The resulting construct was digested by Pst I/Xho 
I to release the puromycin resistant gene. The vector 
was then ligated with Sbf I/Xho I flanking the hygromy-
cin resistant gene using Zero blunt PCR cloning kit (Life 
Technologies). After amplification and purification, vec-
tors were confirmed by sequencing. Viral vectors were 
produced by Fugene transfection in 293T cells using plas-
mids pCMV∆R8.2 and pMD.G as described above and 
used to infect Jurkat hT5Cyp S322 or H126Q cells. Cells 
were selected in 250 μg/mL hygromycin for 1 week and 
clones were isolated by limiting dilution in 96 well plates. 
Nup153 depletion was confirmed by Western blot.
CsA washout assays
Jurkat cells expressing T5Cyp S322 and H126Q have 
been previously described [60]. Cells were seeded in 96 
well plates (100  μL final volume at 106 cells/mL), drugs 
were added at a final concentration of 1  μM (CsA) or 
3 μM (C-A1) and incubated on ice for 15 min in the dark. 
Plates were then incubated on ice for 15 min, virus was 
added and cells were spinoculated for 1.5  h, 1200×g at 
4 °C. After spinoculation, media was replaced at different 
time points and cells were analyzed by flow cytometry 
48 h post-infection. To calculate ToU50, the background 
infection detected in control samples (no CsA added) 
was subtracted and the percentage of GFP+ cells was 
plotted at each time point. Curve fitting was performed 
with software XLfit (ID Business Solutions Ltd.) using the 
Eadie-Hofstee algorithm for all data shown in Fig. 4.
Cell fractionation
Cell fractionation was performed as previously described 
[50] with minor modifications. 107 cells were washed 
once in 500  µL ice cold PBS and once in ice cold iso-
tonic buffer (20 mM HEPES pH7.4, 110 mM KCL, 5 mM 
MgCl2, 0.5 mM EDTA, 1 mM DTT, 20 µg/mL aprotinin, 
20  µg/mL leupeptin). Cells were gently re-suspended in 
100 µL isotonic buffer and 1 mL isotonic buffer+ 0.5 % 
Igepal was added. Cells were incubated on ice for 5 min 
and gently mixed every minute by flicking before cen-
trifugation for 2 min at 2000 rpm in a tabletop centrifuge 
at 4 °C. The supernatant was cleared by centrifugation at 
13,000 rpm for 15 min at 4 °C (the cytoplasmic fraction). 
The pellet (the nuclear fraction) was washed once in iso-
tonic buffer and re-suspended in 1  mL isotonic buffer. 
For Western blot of TRIMCyp, nuclear and cytoplasmic 
fractions were precipitated by adding 10 % (v/v) Trichlo-
roacetic acid (TCA) followed by incubation at −20 °C for 
16 h. Samples were centrifuged at 13,000 rpm for 30 min 
at 4 °C, washed twice with 500 µL ice-cold Acetone, dried 
and re-suspended in 60 μL isotonic buffer.
Western blot
The following primary antibodies were used: anti-HIV-1 
p24/p55 monoclonal antibodies EH12E1 and 3D3, mixed 
and diluted 1/300 (obtained from the AIDS reposi-
tory reagent programme EVA centre for AIDS reagents, 
UK); rabbit polyclonal anti-Nup153 (Sigma-Aldrich 
HPA027896) diluted 1/2000, polyclonal anti-DNA Topoi-
somerase II (Topogen TG2011-1) diluted 1/500, mouse 
monoclonal anti-Na/K ATPase (Santa Cruz sc-58626) 
diluted 1/200, mouse monoclonal anti-Flag M2 (Sigma-
Aldrich F3165) diluted 1/500. Samples were resuspended 
in 2× SDS loading buffer (0.5 M Tris HCl [pH 6.8], 1 % 
SDS, 10  % glycerol, 0.1  % bromophenol blue, 1  mM 
EDTA, 10 mM DTT, 20 µg of aprotinin/mL 2 µg of leu-
peptin hemisulfate/mL, 10  µg of phenylmethylsulfonyl 
fluoride) and the pH was adjusted to ~7.0 by addition of 
1 µL of 1.5 M Tris–HCl (pH 8.8). Samples were resolved 
onto a 4–12 % gradient SDS-PAGE (pre-cast gel, Invitro-
gen) and transferred to a nitrocellulose membrane (Bio-
Rad) [24]. Anti-mouse IgG HRP-conjugated antibodies 
were purchased from Dako (P0447) and diluted 1/5000 in 
10 % non-fat milk (Tesco, London, UK); IgG HRP-conju-
gated anti-rabbit antibodies were also from Dako (P0448) 
and diluted 1/3000. Following transfer, the membrane 
was incubated with primary antibodies overnight at 4 °C 
and with secondary antibodies for 1 h at room tempera-
ture. Enhanced chemiluminescence (ECL Prime—Amer-
sham) was used to develop the blots. Autoradiography 
films were exposed for different periods of time to ensure 
linearity of the signal.
CPSF6 binding assays
Human 293T cells were transfected with plasmids 
expressing the CPSF6-FLAG protein. Twenty-four 
hours after transfection, cell were harvested, washed 
and resuspended in an hypotonic lysis buffer (10 mM 
Tris [pH 7.4], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithi-
othreitol [DTT]). The cell suspension was incubated on 
ice for 10  min. Afterwards lysates were centrifuged at 
maximum speed in a refrigerated Eppendorf microcen-
trifuge (14,000×g) for 5  min. 4–5  μL of in  vitro assem-
bled HIV-1 capsid–nucleocapsid (CA–NC) complexes 
were incubated with 200 μl of cell lysates containing 0,1, 
5 and 10  μM C-A1. Mixtures were incubated at room 
Page 14 of 16Chen et al. Retrovirology  (2016) 13:28 
temperature for 1 h. 6 μM of PF74 was used as control. 
A fraction of these samples was stored (input). Mixtures 
were spun through a sucrose cushion (70  % sucrose, 
1× PBS, 0.5 mM DTT) at 100,000×g in an SW55 rotor 
(Beckman) for 1  h at 4  °C. After centrifugation, the 
supernatant was carefully removed, and the pellets were 
resuspended in 1× SDS-PAGE loading buffer (pellet). 
The effect of C-A1 on CPSF6 binding to HIV-1 CA–NC 
complexes was determined by Western blotting using 
anti-FLAG antibodies. Levels of HIV-1 CA–NC com-
plexes in the pellet was determined by Western blotting 
using anti-p24 CA antibodies. Fluorescent Wester b blot-
ting allowed the quantification of bands in the 680  nm 
channels.
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Additional files
Additional file 1: Fig. S1. Docking of C‑A1 into HIV‑1 into hexameric 
capsid bound to PF‑74 (4XFZpdb). Molecular docking was performed 
using the dock module within MOE software and the two subunits 
of capsid are depicted in pink and grey respectively. Key interactions 
between capsid and C‑A1 (yellow) or PF74 (green) are depicted along 
with predicted hydrogen bonds and vdWaals contacts.
 Additional file 2: Fig. S2. Diagrammatic representation of the CsA 
washout assay.
 Additional file 3: Fig. S3. Conditions of the CsA washout assay. (A) 
T5Cyp and H126Q Jurkat cells were infected with increasing amounts of a 
WT HIV‑1GFP vector and analysed by FACS 36‑48 h later to determine the 
level of restriction and the linearity of infection. The same titrations were 
performed using N74D (B) and A105S (C) viruses. (D) Table summarizing 
the titration results for panels (A, B and C); the percentage of GFP+ cells is 
shown for each virus dilution. (E) T5Cyp or H126Q cells were infected with 
WT HIV‑1GFP in the presence of the indicated doses of CsA and analysed 
by FACS 48 h later. (E) Samples in (E) were gated such that cells that did 
not fall within the forward/side scatter gate established for untreated (no 
CsA) cells were considered dead.
 Additional file 4: Fig. S4. Conditions for the CsA washout assay. (A) 
H126Q cells were infected with WT HIV‑1GFP vector by spinoculation in the 
presence of CsA (1 μM) or C‑A1 (3 μM). The drug was washed out at the 
indicated time points (time of washout) and cells were analysed by FACS 
48 h later to determine the percentage of infected (GFP+) cells. (B) Same 
as (A) but T5Cyp cells expressing functional human TRIMCyp were used. 
(C) A prolonged time of uncoating assay, in which CsA was washed out at 
the indicated time points. Rescue of infection reaches a plateau after 10 h. 
Average ± SD of three independent experiments are shown in (A‑C).
Additional file 5: Fig. S5. CsA washout assays in cells depleted of 
Nup153 or control DsRed cells. T5Cyp cells expressing an shRNA against 
Nup153 or DsRed (control) were infected at an MOI of 0.01–0.05 with an 
HIV‑1GFP vector (WT) in the presence of CsA (1 μM). The drug was washed 
out at the indicated time points (time of washout) and cells were analysed 
by FACS 48 h later to determine the percentage of infected (GFP+) cells. 
To control for specificity, cells were infected in the same way using the 
N74D mutant virus. Raw data of three independent experiments are 
shown. The data have been used to compile fold rescue levels shown in 
Figure 6.
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